Channel Medsystems, a commercial-stage women’s health company, announced today that more than 5,000 women have now been treated with the Cerene Cryotherapy Device, underscoring the growing clinical and commercial adoption of the company’s innovative solution for heavy menstrual bleeding (HMB) and dysmenorrhea.
Cerene is an FDA-approved endometrial cryoablation device designed to be used in a gynecologist’s office without general anesthesia or operating-room resources. The milestone reflects expanding adoption across hospitals, ambulatory surgery centers, and private OB/GYN practices nationwide.
“Reaching 5,000 cases demonstrates how quickly Cerene has become an integral part of the modern gynecologist’s toolkit,” said Paul Russo Vice President of Sales at Channel Medsystems. “Physicians appreciate its ease of use, patients appreciate the comfort and safety, and health systems appreciate the efficiency and economics of an in-office treatment that delivers long-term relief.”
The 5,000-procedure milestone follows a period of accelerated momentum for Channel Medsystems, which continues to expand its national footprint through commercial team growth, strategic partnerships, physician education programs, and growing payer coverage. The company’s focus on advancing cryotherapy as a new standard of care in heavy menstrual bleeding supports its mission to empower every woman to takecontrol of her health journey.
“Each Cerene procedure represents a woman choosing to address heavy bleeding and dysmenorrhea in a way that fits her life,” said Nelson Whistance, President and Chief Executive Officer of Channel Medsystems. “This milestone validates both the clinical impact of cryotherapy and the dedication of our growing network of providers who are redefining care for women everywhere.”
